Open AccessFc RIIIA and Fc RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Author(s) -
Emanuela Carlotti,
Giuseppe A. Palumbo,
Elena Oldani,
Daniele Tibullo,
Silvia Salmoiraghi,
Andrea Rossi,
Josée Golay,
Alessandro Pulsoni,
Robin Foà,
Alessandro Rambaldi
Publication year - 2007
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.11288
Subject(s) - rituximab , medicine , follicular lymphoma , lymphoma , chop , oncology , cohort , immunology , gastroenterology
We analyzed FcgammaRIIIA-158V/F and FcgammaRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcgammaRIIIA-158VV/VF and FcgammaRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.